Abstract 23P
Background
PMC-309 is a novel human monoclonal IgG1 antibody (mAb). It binds with human VISTA, an immune checkpoint protein, with the effect of regulating the immunological activity of myeloid cells such as MDSC or myeloid-derived immune cells, thereby improving the antitumor activities of immune cells. In addition to being a novel drug substance, PMC309 will be the first IgG1 monoclonal antibody to act synergistically with other immunotherapies to improve treatment efficacy.
Methods
In vitro T cell activity: human PBMC was employed for the evaluation of T cell activity, and was stimulated with or w/o PMC-309 in the presence of anti-CD3/28 Antibody. In vivo study: MC38-bearing human VISTA knock-in (KI) mice were employed for the assessment of the anti-tumor activity of PMC-309. The tumor infiltrated immune cells: Immune cells in the TME were evaluated by immunohistochemistry (IHC) or flow cytometry (FACS) analysis.
Results
PMC-309 binding to VISTA-expressing cells is highly selective and the selectivity is maintained even in the low pH conditions that mimic TME. PMC-309 enhances the secretion of IFN-gamma, TNF-alpha, and IL-2 in Mixed Lymphocyte Reaction (MLR) settings. In addition, PMC-309 promoted monocyte differentiation into M1 macrophage which stimulates proinflammatory cytokine secretion of T cells. For the in vivo study, PMC-309 was intravenously administrated in VISTA-KI mice. The tumor growth rate was suppressed accompanied by a synergistic effect with an anti-PD1 antibody. The anti-tumor activity was associated with enhanced T cell activation, increased secretion of pro-inflammatory cytokines, and increased penetration of cytotoxic T cells, but lowing immune-suppressive MDSC cells into TME as demonstrated with IHC analysis.
Conclusions
PMC-309 enhanced both T-cell activation and monocyte activation. PMC-309 increased the number of T cell infiltration while a decrease of MDSCs in the TME. PMC-309 in combination with chemotherapy or other IO drugs could address the high medical unmet needs of patients with drug resistance to currently available IO treatment options.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
PharmAbcine Inc.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
57P - Metastasis organotropism: Unveiling associated proteins using network biology
Presenter: Margarida Carrolo
Session: Poster session 09
59P - Correlation of tumor microenvironment signature in advanced stage non-small cell lung cancer with EGFR mutation who received EGFR-TKIs
Presenter: Chaiyapong Ngamchokwathana
Session: Poster session 09
60P - Establishment and characterization of a novel lung adenocarcinoma cell line HX-JCJ harboring MET ex14 skipping mutation
Presenter: Xuejin Ou
Session: Poster session 09
61P - Next generation sequencing and its clinical utility in advanced cancer: Single institute experience from low-middle income country
Presenter: Amit Badola
Session: Poster session 09
62P - Prebiotics modulate gut microbiota-mediated T cell immunity to enhance sintilimab inhibition of lung cancer
Presenter: QIN YAN
Session: Poster session 09
63P - Addition of human chorionic gonadotropin to the current standard mobilization approach with granulocyte-colony stimulating factor increases overall survival in a murine model of peripheral blood stem cell transplantation: Are we far enough for therapy?
Presenter: Andrei Cismaru
Session: Poster session 09
64P - Developing novel therapeutics for bladder cancer leveraging drosophila models
Presenter: Takuya Moriguchi
Session: Poster session 09
65P - Ionizing radiation induces vascular smooth muscle cell senescence through activating NF-κB-CTCF-p16 pathway
Presenter: xuefeng zheng
Session: Poster session 09
66P - Exploring the radiobiology and dosimetry of targeted alpha therapy as a tool to optimize its clinical application: A preclinical study
Presenter: Maria Filomena Botelho
Session: Poster session 09
67P - The effect of non-viral gene-immune therapy via OX40L or 4-1BBL on murine subcutaneous CT26 colon cancer model
Presenter: Olga Rakitina
Session: Poster session 09